2023-03-15 16:19:15 ET
- Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q4 Non-GAAP EPS of $0.31 beats by $0.11 .
- Revenue of $60.76M (+58.6% Y/Y) beats by $0.12M .
- Cash and Equivalents were $298 million as of December 31, 2022.
- Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase
- Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY Increase
- Newly Acquired FYCOMPA® Product Expected to be Accretive to EBITDA and EPS in 2023
- Reaffirming Forecast of 2023 Total Net Product Revenues, including FYCOMPA, of between $375 Million and $385 Million
- Recently Acquired Patents Further Strengthens FIRDAPSE Long-Term Commercial Potential to 2037 .
- Shares +0.7% .
For further details see:
Catalyst Pharmaceuticals Non-GAAP EPS of $0.31 beats by $0.11, revenue of $60.76M beats by $0.12M